Ludacure

Ludacure is a South Korean biotechnology company headquartered in Incheon, focused on developing first-in-class therapies for ocular, inflammatory, and nervous system diseases. The company's research is centered on its proprietary RAC1 inhibition platform and TRPV1 modulation technology. Its lead candidate, RCI-001, is currently in Phase 2 clinical development for dry eye syndrome and other ocular surface diseases. Ludacure also maintains a robust discovery pipeline, including RCI-004 for melanoma (partnered with Syntekabio) and RCI-002 for peripheral nervous system disorders. Additionally, the company offers RDscan, a bioinformatics tool for high-precision variant calling in genomic data.